Population Pharmacokinetic Analysis of Sparsentan in Healthy Volunteers and Patients with Focal Segmental Glomerulosclerosis

The Dual Endothelin A and Angiotensin II Type 1 Receptor Antagonist Sparsentan (FILSPARI®) Exhibits a Safe Nonclinical Male Fertility Toxicity Profile

Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: An Open-Label Drug–Drug Interaction Study in Healthy Adults

Physiologically-Based Pharmacokinetic Model of Sparsentan to Evaluate Drug-Drug Interaction Potential